Avycaz For Injection - (0.5 g/2 g per vial)

Generic Name	Avibactam Sodium and Ceftazidime	Innovator	Allergan
Dosage	0.5 g/2 g per vial	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	AVYCAZ (ceftazidime-avibactam) is a combination of a cephalosporin and a beta-lactamase inhibitor indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms: • Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole • Complicated Urinary Tract Infections (cUTI), including Pyelonephritis.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
**** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
*********	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events